Markets:

Overview

News

Currencies

International

Treasuries

Myovant Sciences Ltd. Common Shares (NY:MYOV)

N/A UNCHANGED

Last Price Updated: 7:00 PM EST, Mar 9, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Myovant Sciences Ltd. Common Shares

< Previous 1 2 3 4 5 Next >

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

July 07, 2022

Gainers

Via Benzinga

FDA Accepts Myovant Sciences and Pfizer's Filing For Review In Uterine Fibroids ↗

June 02, 2022

Myovant Sciences (NASDAQ: MYOV) and Pfizer (NASDAQ: PFE) received U.S.

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates ↗

May 31, 2022

May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,...

Via Benzinga

Urovant's OAB Gene Therapy Shows Improvement In Symptoms Compared To Placebo ↗

May 13, 2022

Urovant Sciences' interim results from a Phase 2a trial of URO-902 gene therapy were presented at the annual meeting of the American Urological Association (AUA2022). Urovant is a wholly-owned...

Via Benzinga

Myovant Sciences: Q4 Earnings Insights ↗

May 10, 2022

Myovant Sciences (NYSE:MYOV) reported its Q4 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Myovant, Accord Healthcare Ink Relugolix Distribution Pact For Europe In Prostate Cancer ↗

May 09, 2022

Via Benzinga

Myovant Sciences' Relugolix For Hormone-Sensitive Prostate Cancer Approved In Europe ↗

May 02, 2022

Via Benzinga

103 Biggest Movers From Yesterday ↗

May 11, 2022

Gainers

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

May 10, 2022

Via Benzinga

77 Stocks Moving In Tuesday's Mid-Day Session ↗

May 10, 2022

Gainers

Via Benzinga

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗

May 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Earnings Preview: Myovant Sciences ↗

May 09, 2022

Myovant Sciences (NYSE:MYOV) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Myovant...

Via Benzinga

U.S. FDA extends review of Pfizer and Myovant Sciences supplemental New Drug Application (sNDA) For MYFEMBREE by three months ↗

May 06, 2022

The U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) from Pfizer Inc.

Via Benzinga

Here's Why This Analyst Is On Sidelines Despite European Approval Of Myovant's Relugolix For Prostate Cancer ↗

May 02, 2022

Via Benzinga

The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More ↗

May 02, 2022

Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates ↗

May 01, 2022

The month of April was a mixed one for regulatory approvals. The Food and Drug Administration delayed approvals for at least three treatment candidates. New molecular entity, or NME, approvals, a...

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

April 21, 2022

On Thursday, 236 companies hit new 52-week lows.

Via Benzinga

SVB Leerink Maintains Market Perform Rating for Myovant Sciences, Lowers Price Target To $12 ↗

April 13, 2022

SVB Leerink has decided to maintain its Market Perform rating of Myovant Sciences (NYSE:MYOV) and lower its price target from $19.00 to $12.00. Shares of Myovant Sciences are trading up 8.08% over the...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

April 12, 2022

Gainers

Via Benzinga

Dow, Nasdaq Up Triple Digits as Wall Street Bets on Inflation's Top ↗

April 12, 2022

Despite a slightly hotter-than-expected March consumer price index (CPI) reading earlier today, stocks are moving higher, as Wall Street bets on inflation's peak.

Via Talk Markets

Myovant Sciences Collapses As FDA Holdup Snags Its Blockbuster Potential ↗

April 12, 2022

The Pfizer-partnered endometriosis drug is facing additional FDA scrutiny.

Via Investor's Business Daily

What's Going On With Myovant Sciences Stock Today? ↗

April 12, 2022

Myovant Sciences Ltd (NYSE: MYOV) shares are trading significantly lower Tuesday after the company and Pfizer Inc (NYSE: PFE) announced an update on the Supplemental New...

Via Benzinga

The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More ↗

April 12, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Urovant Reports Publication of New Efficacy, Safety Data On Gemtesa For Overactive Bladder ↗

March 22, 2022

Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd, announced the

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

March 16, 2022

Gainers

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

February 25, 2022

Gainers Surgalign Holdings (NASDAQ:SRGA) ...

Via Benzinga

Bear Market Bets In Biotech ↗

February 07, 2022

Taken together, the SPDR S&P Biotech ETF easily broke below the long-term 200-week support for the first time since the pandemic originally hit the markets in March of 2020.

Via Talk Markets

Myovant Sciences's Return on Invested Capital Insights ↗

January 27, 2022

Myovant Sciences (NYSE:MYOV) brought in sales totaling $54.44 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 193.85%, resulting in a...

Via Benzinga

Myovant Sciences: Q3 Earnings Insights ↗

January 26, 2022

Myovant Sciences (NYSE:MYOV) reported its Q3 earnings results on Wednesday, January 26, 2022 at 07:00 AM. Here's what investors need to know about the announcement....

Via Benzinga

Earnings Scheduled For January 26, 2022 ↗

January 26, 2022

Companies Reporting Before The Bell • Blue Foundry (NASDAQ:BLFY) is projected to report earnings for its fourth quarter. • First BanCorp (NYSE:FBP) is likely to...

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Myovant Sciences Ltd. Common Shares (NY:MYOV)

All News about Myovant Sciences Ltd. Common Shares

Starting at $3.75/week.

Subscribe Today